Skip to main content
Journal cover image

Improving outcomes in scleroderma: recent progress of cell-based therapies.

Publication ,  Journal Article
Khanna, D; Krieger, N; Sullivan, KM
Published in: Rheumatology (Oxford)
June 1, 2023

Scleroderma is a rare, potentially fatal, clinically heterogeneous, systemic autoimmune connective tissue disorder that is characterized by progressive fibrosis of the skin and visceral organs, vasculopathy and immune dysregulation. The more severe form of the disease, diffuse cutaneous scleroderma (dcSSc), has no cure and limited treatment options. Haematopoietic stem cell transplantation has emerged as a potentially disease-modifying treatment but faces challenges such as toxicity associated with fully myeloablative conditioning and recurrence of autoimmunity. Novel cell therapies-such as mesenchymal stem cells, chimeric antigen receptor-based therapy, tolerogenic dendritic cells and facilitating cells-that may restore self-tolerance with more favourable safety and tolerability profiles are being explored for the treatment of dcSSc and other autoimmune diseases. This narrative review examines these evolving cell therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Rheumatology (Oxford)

DOI

EISSN

1462-0332

Publication Date

June 1, 2023

Volume

62

Issue

6

Start / End Page

2060 / 2069

Location

England

Related Subject Headings

  • Skin
  • Scleroderma, Systemic
  • Scleroderma, Localized
  • Scleroderma, Diffuse
  • Immune Tolerance
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Autoimmunity
  • Arthritis & Rheumatology
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khanna, D., Krieger, N., & Sullivan, K. M. (2023). Improving outcomes in scleroderma: recent progress of cell-based therapies. Rheumatology (Oxford), 62(6), 2060–2069. https://doi.org/10.1093/rheumatology/keac628
Khanna, Dinesh, Nancy Krieger, and Keith M. Sullivan. “Improving outcomes in scleroderma: recent progress of cell-based therapies.Rheumatology (Oxford) 62, no. 6 (June 1, 2023): 2060–69. https://doi.org/10.1093/rheumatology/keac628.
Khanna D, Krieger N, Sullivan KM. Improving outcomes in scleroderma: recent progress of cell-based therapies. Rheumatology (Oxford). 2023 Jun 1;62(6):2060–9.
Khanna, Dinesh, et al. “Improving outcomes in scleroderma: recent progress of cell-based therapies.Rheumatology (Oxford), vol. 62, no. 6, June 2023, pp. 2060–69. Pubmed, doi:10.1093/rheumatology/keac628.
Khanna D, Krieger N, Sullivan KM. Improving outcomes in scleroderma: recent progress of cell-based therapies. Rheumatology (Oxford). 2023 Jun 1;62(6):2060–2069.
Journal cover image

Published In

Rheumatology (Oxford)

DOI

EISSN

1462-0332

Publication Date

June 1, 2023

Volume

62

Issue

6

Start / End Page

2060 / 2069

Location

England

Related Subject Headings

  • Skin
  • Scleroderma, Systemic
  • Scleroderma, Localized
  • Scleroderma, Diffuse
  • Immune Tolerance
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Autoimmunity
  • Arthritis & Rheumatology
  • 3204 Immunology